Research

Everything here about research studies, trials and reviews: our articles first, then short answers, the words you may hear, and the original sources.

Articles

Common questions 10

What is the CDAI, and how is it different from the HBI?

The Crohn's Disease Activity Index (CDAI) is an older, longer score. It needs a 7-day symptom diary, your weight and a blood test result, so it takes more effort to work out. A CDAI under 150 is taken as a marker of remission and over 450 as a marker of severe Crohn's. The Harvey-Bradshaw Index is a simpler score based on just the previous day's symptoms and does not need a blood test.

Sources

What does 'treat to target' mean?

It means your team agrees goals in advance and adjusts treatment until you reach them, rather than waiting for symptoms. The STRIDE-II expert agreement says early goals are feeling better and getting blood and poo inflammation tests back to normal; longer-term goals are a healed bowel lining, no disability, good quality of life and normal growth in children. The CALM trial found that stepping up treatment when tests showed inflammation, not just when symptoms flared, led to more bowel healing.

Sources

How do I take part in Crohn's research?

Ask your IBD team whether your hospital is running any studies. You can also search the NIHR's Be Part of Research website, which lists UK studies currently recruiting people with Crohn's. The IBD BioResource invites people with Crohn's or colitis to join a national panel and be contacted about future studies. Crohn's & Colitis UK also lists ways to help shape research, such as patient and public involvement.

Sources

What is 'top-down' treatment and is it better?

Top-down means starting strong treatment, such as a biologic plus an immunosuppressant, soon after diagnosis instead of trying milder medicines first ('step-up'). In the UK PROFILE trial of newly diagnosed adults, 79% on top-down treatment stayed in remission without steroids or surgery for a year, compared with 15% on step-up, with fewer flares and operations. Your team will weigh this up for your own situation.

Source

Which biologic is best for Crohn's?

There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.

Sources

Do probiotics or a poo transplant help Crohn's?

We do not know yet. Cochrane found only two small trials of probiotics for active Crohn's and called the evidence very uncertain. For faecal microbiota transplant (putting donor poo into the bowel), Cochrane also found the evidence in Crohn's too uncertain to draw any conclusions. Both are areas of ongoing research.

Sources

Is Crohn's disease genetic?

Partly. In 2001 researchers found the first gene firmly linked to Crohn's, NOD2, which helps the immune system recognise bacteria. Later large studies found many more gene regions, each adding a small amount of risk, and many are shared with other immune conditions. Having these gene changes does not mean you will get Crohn's; gut bacteria and environment also play a part.

Sources

What standard of care should I expect from my IBD service?

The IBD Standards, written by the IBD UK alliance, set out what good care looks like across the whole journey, from before diagnosis to flares, surgery, hospital stays and ongoing care. IBD UK's reports show many services fall short, for example with long waits for diagnosis and too few IBD nurses, dietitians and psychologists.

Sources

What is a Cochrane review and why does it matter?

Cochrane reviews are systematic reviews: researchers find every good trial on a question, judge how reliable each one is and combine the results. They also grade how certain the evidence is. For Crohn's, Cochrane has found strong evidence for some treatments, such as vedolizumab, and too little evidence to judge others, such as treatments for fatigue.

Sources

How can I take part in a Crohn's clinical trial?

The NHS suggests asking your doctor or a patient organisation about trials you may be eligible for. You can also search the NIHR's Be Part of Research website for UK studies and contact research teams directly. Registries such as ISRCTN and ClinicalTrials.gov list studies and their results. Crohn's & Colitis UK explains how new medicines are tested before they are licensed.

Sources

Words you might hear 50

Absolute risk
The actual chance of something happening, such as 5 in 100 people. Easier to understand than relative risk, because a 'doubled' risk may still be very small.
Adverse event
Any unwanted health problem that happens during a trial, whether or not the treatment caused it. A 'serious adverse event' is one that is life-threatening or leads to hospital.
Biologic-naive
Describes someone who has never had a biologic medicine before. Trials often report results separately for these people because first biologics tend to work better.
Biomarker
Something measurable in the body, such as a blood or poo test result, that gives information about disease or how it might behave. CRP and faecal calprotectin are examples.
Case report
A write-up of what happened to one patient (or a few, in a case series), usually because it was unusual. Useful for spotting rare problems, but too small to show what is typical.
Case-control study
A study that compares people who have a condition with similar people who do not, looking back to find differences that might explain it.
Certainty of evidence
How confident researchers are that a result is true, often graded high, moderate, low or very low. 'Very low certainty' means future research could easily change the answer.
Clinical remission
When your symptoms have settled, judged by a symptom score or how you feel. It does not always mean the inflammation inside the bowel has gone.
Clinical trial
A research study that tests whether a treatment is safe and works, often comparing it with placebo or another treatment.
Cochrane review
A systematic review produced to strict standards by Cochrane, an independent international network. Widely trusted as one of the most reliable summaries of evidence.
Cohort study
A study that follows a group of people over time to see what happens to them, without giving them a treatment. Good for finding links, but cannot prove cause and effect on its own.
Confidence interval
The range in which the true result probably lies. A narrow range means a more precise result; if the range for a difference includes zero (or 1 for a ratio), the result may be due to chance.
Crohn's disease activity index
A longer score of Crohn's activity using a 7-day symptom diary, weight and a blood test, mainly used in drug trials. Under 150 usually means remission.
Deep remission
Being in both clinical remission (no symptoms) and endoscopic remission (healed lining) at the same time.
Double-blind
A trial where neither the patients nor the doctors know who is getting the real treatment and who is getting placebo, so expectations cannot sway the results.
Endoscopic remission
When a camera test (colonoscopy or similar) shows the bowel lining no longer has active inflammation or ulcers.
Endpoint
The main result a trial is designed to measure, decided before it starts, such as the number of people in remission at one year.
Epidemiology
The study of how common a disease is, who gets it, where, and why.
Faecal microbiota transplant
Putting processed poo from a healthy donor into someone's bowel to change their gut bacteria. Experimental in Crohn's.
Genome-wide association study
A study that scans the DNA of thousands of people with and without a condition to find gene regions linked to it.
Guideline
Recommendations for doctors on how to diagnose and treat a condition, usually written by an expert panel after reviewing the evidence. Examples are NICE, BSG and ECCO guidelines.
Hazard ratio
Compares how quickly something (such as a flare, operation or death) happens over time in one group compared with another. Below 1 means it happens less often or later.
Head-to-head trial
A trial that compares two active treatments directly, rather than comparing a treatment with placebo.
Incidence
How many new cases of a condition appear in a group of people over a set time, usually given per 100,000 people per year.
Induction
The first phase of treatment, aimed at bringing a flare under control. Often uses higher or more frequent doses.
Maintenance
Ongoing treatment given after a flare has settled, to keep the disease quiet and stop it coming back.
Meta-analysis
A way of combining the numbers from several studies into one overall result, which is more reliable than any one small study.
Microbiome
The huge community of bacteria and other microbes living in your gut. In Crohn's the balance is often different from people without it.
Mucosal healing
When the gut lining looks healed on a camera test, not just when symptoms have settled. Many IBD teams now aim for this as a treatment goal.
Network meta-analysis
A meta-analysis that compares many treatments at once, including pairs that were never tested against each other directly, by linking them through shared comparisons such as placebo.
Nod2
The first gene found to be linked to Crohn's (in 2001). It helps the immune system recognise bacteria; certain changes in it raise the risk of Crohn's.
Non-inferiority
A trial design that checks whether a new treatment is 'not worse' than an existing one by more than an agreed small amount.
Number needed to treat
How many people need to have a treatment for one extra person to benefit compared with placebo or another treatment. Smaller is better.
Odds ratio
Another way of comparing how likely something is between two groups. Similar in meaning to relative risk when the event is uncommon.
Open-label
A trial where everyone knows which treatment they are getting. Sometimes unavoidable, for example when comparing surgery with a drug or one diet with another.
P-value
A number that shows how likely a result could have happened by chance alone. By convention, below 0.05 is called 'statistically significant', but that does not always mean the difference matters in real life.
Patient and public involvement
When people with a condition help plan, run or explain research, for example by commenting on study designs or patient leaflets.
Phase 3 trial
A large trial, usually in hundreds or thousands of people, done to confirm a drug works and is safe enough before it is licensed. Phase 1 and 2 trials are smaller and earlier.
Placebo
A dummy treatment that looks like the real one but contains no active drug. Used in trials so researchers can tell how much of any improvement is due to the drug itself.
Prevalence
How many people are living with a condition at a given time. Incidence is how many new cases are diagnosed each year.
Randomised controlled trial
A study where people are put into groups by chance (like tossing a coin) to get different treatments, so the groups can be fairly compared. It is the most reliable way to test whether a treatment works.
Refractory
Describes disease that has not responded to standard treatments.
Relative risk
How much more (or less) likely something is in one group compared with another. A relative risk of 2 means twice as likely; 0.5 means half as likely.
Step-up treatment
Starting with milder medicines and moving on to stronger ones only if the milder ones do not work.
Steroid-free remission
Being in remission without needing steroid medicines such as prednisolone. A tougher, more meaningful goal than remission alone because steroids have many side effects.
Systematic review
A study that searches for every good piece of research on one question, checks how reliable each one is, and sums up what they show together.
Top-down treatment
Starting strong treatment such as a biologic, often with an immunosuppressant, soon after diagnosis, instead of trying milder medicines first.
Transmural healing
Healing through the whole thickness of the bowel wall, usually checked by a scan such as MRI or bowel ultrasound. A deeper level of healing than the lining alone.
Treat to target
An approach where treatment is adjusted until measured goals are met, such as normal calprotectin or a healed gut lining, rather than only until symptoms improve.
Trial registry
A public database where studies are recorded before they start, so anyone can see what is being tested and check results are reported. ISRCTN and ClinicalTrials.gov are examples.

Further reading 71

The original NHS, NICE, charity and research pages on this topic, with our summary of each.

Guides for patients and families

Web pages 6

Clinical trials

NHS Web page Dec 2022 For patients

The NHS explains what a clinical trial is and how to find one. It suggests asking your doctor or a patient organisation, and points to the Be Part of Research website, where you can search UK studies and contact researchers.

Topics Research

Jargon explained clinical trial randomised

Want to get involved in research?

Crohn's & Colitis UK Web page For patients

Crohn's & Colitis UK's starting point for people who want to help with research. It explains patient and public involvement, where people with Crohn's help shape studies, and the charity's Research Champions, and lists current opportunities.

Topics Research

Jargon explained patient and public involvement

About our Research

Crohn's & Colitis UK Web page Patients and professionals

Explains how Crohn's & Colitis UK funds research, including its 2026-2030 research strategy, the projects it is funding and the difference past research has made. The charity says it has funded research since 1979.

Topics Research

Jargon explained research strategy grant

IBD BioResource

NIHR BioResource Web page Patients and professionals

A national NIHR project that builds a large panel of people with Crohn's and colitis who agree to share samples and health data and to be invited into future studies. It aims to understand the genetic causes of IBD and why people respond differently to treatment. There is also a children's arm.

Topics Research

Jargon explained bioresource cohort genetic analysis

New research shows over 1 in 123 people in UK living with Crohn's or Colitis

Crohn's & Colitis UK Web page Mar 2022 Patients and professionals

Reports a University of Nottingham study, funded by the charity and Coeliac UK, that looked at GP records for 38.3 million people. It found more than half a million people in the UK, about 1 in every 123, live with Crohn's, ulcerative colitis or unclassified IBD, almost twice the previous estimate of 300,000.

Topics About Crohn's disease Research

Jargon explained prevalence incidence

Guides 1

Tools 3

Be Part of Research

NIHR Tool For patients

The NHS research service's search tool for finding health studies to take part in across the UK. Searching for Crohn's disease lists studies currently recruiting, with who can join and where. A good first stop if you want to volunteer for a trial.

Topics Research

Jargon explained clinical trial recruiting

ISRCTN Registry

ISRCTN Tool Patients and professionals

A WHO-recognised registry where UK and international studies are recorded before they start, with their aims and progress. You can search it free for Crohn's studies, including UK trials such as PROFILE. Records are written for researchers, so they can be technical.

Topics Research

Jargon explained trial registry study protocol ISRCTN number

Guidelines 1

IBD Standards 2026

IBD UK Guideline 2026 Patients and professionals

The UK-wide standards for IBD care from the IBD UK alliance, updated in 2026 with 60 statements built on the experiences of about 26,000 patients. The pre-diagnosis section calls for local referral pathways using calprotectin and/or FIT, a specialist appointment or straight-to-test within four weeks of referral, and endoscopy and scans within 6 weeks for routine care and 2 weeks if urgent, favouring MRI and ultrasound because they avoid radiation. A patient version is available.

Topics Diagnosis and tests Monitoring Living well Research

Jargon explained faecal calprotectin faecal immunochemical test referral MRI enterography intestinal ultrasound IBD Standards multidisciplinary team

Reports 2

Crohn's and Colitis Care in the UK: The Hidden Cost and a Vision for Change

IBD UK Report Apr 2021 Patients and professionals

IBD UK's 2021 report, drawing on more than 10,000 patients and most UK IBD services. It found people waited too long for diagnosis, pain, fatigue and emotional wellbeing were often ignored, specialist help was slow, there were too few IBD nurses, dietitians and psychologists, and care was often not joined up.

Topics Research Living well Diagnosis and tests

Jargon explained benchmarking IBD nurse specialist

Systematic reviews 20

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis

Cochrane Systematic review Jun 2026 Patients and professionals

An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.

Topics Biologics and newer medicines Research

Jargon explained network meta-analysis relative risk number needed to treat biosimilar

Psychological interventions in inflammatory bowel disease

Cochrane Systematic review Apr 2025 Patients and professionals

A plain-language summary of a Cochrane review. It concludes that psychological treatments probably give a small improvement in quality of life, depression and anxiety in adults with IBD, and probably improve quality of life in teenagers. Any effect on inflammation or physical symptoms is very uncertain.

Topics Mental health Research

Jargon explained psychological interventions systematic review

Vedolizumab for induction and maintenance of remission in Crohn's disease

Cochrane Systematic review Jul 2023 Patients and professionals

Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.

Topics Biologics and newer medicines Research

Jargon explained high-certainty evidence induction maintenance integrin

Interventions for treating iron deficiency anaemia in inflammatory bowel disease

Cochrane Systematic review Jan 2021 Patients and professionals

Looks at iron tablets and iron drips for anaemia caused by low iron in IBD. The reviewers found the evidence too weak to say for certain which works best, even though both are widely used and guidelines favour drips. They highlight this as an important gap.

Topics Anaemia Research

Jargon explained iron deficiency anaemia intravenous iron ferric carboxymaltose

Treatments for extreme tiredness and lack of energy (fatigue) in inflammatory bowel disease

Cochrane Systematic review Apr 2020 Patients and professionals

A Cochrane review of 14 studies, covering both drug and non-drug treatments such as exercise and psychological approaches, for fatigue in IBD. The reviewers concluded the evidence is too uncertain to say which treatments work and called for trials designed specifically around fatigue.

Topics Fatigue Research

Jargon explained fatigue systematic review

Diets for inducing and maintaining remission in inflammatory bowel disease (IBD)

Cochrane Systematic review Feb 2019 Patients and professionals

A Cochrane review of 18 trials that tested cutting down or cutting out foods thought to provoke IBD symptoms. The authors found the evidence too weak to say whether any of these diets help bring on or keep remission, and called for better trials. This summary dates from 2019.

Topics Diet and nutrition Research

Jargon explained remission exclusion diet randomised controlled trial

Antibiotics for induction and maintenance of remission in Crohn's disease

Cochrane Systematic review Feb 2019 Patients and professionals

Antibiotics may give a small benefit for active Crohn's, but probably not enough to make a real difference for most people. They did not cause more side effects than placebo. Whether they help keep Crohn's in remission is unclear. Note this is about treating the Crohn's itself, not infections or abscesses.

Topics Medicines Research

Jargon explained antibiotic clinically meaningful antibiotics induction maintenance

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

Cochrane Systematic review Oct 2015 Patients and professionals

Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.

Topics Immunosuppressants Research

Jargon explained thiopurine low-quality evidence adverse event remission placebo systematic review

Budesonide for induction of remission in Crohn's disease

Cochrane Systematic review Jun 2015 Patients and professionals

Budesonide, a steroid that acts mainly in the gut, works better than placebo for bringing on remission. It is a bit less effective than standard steroids such as prednisolone, especially for severe or widespread colon disease, but causes fewer side effects and less suppression of the body's own steroid production.

Topics Steroids Research

Jargon explained budesonide corticosteroid adrenal suppression conventional steroids

Methotrexate for maintenance of remission in Crohn's disease

Cochrane (via PMC) Systematic review Aug 2014 Patients and professionals

A Cochrane review finding moderate-quality evidence that methotrexate given by injection helps keep Crohn's in remission and appears safe, while low-dose tablets did not appear effective in the trials reviewed. Adding methotrexate to infliximab did not improve remission rates.

Topics Immunosuppressants Research

Jargon explained methotrexate intramuscular maintenance

Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease

Cochrane (via PMC) Systematic review Aug 2020 Patients and professionals

A Cochrane review suggesting that stepping up treatment based on a colonoscopy after surgery may reduce Crohn's coming back compared with waiting for symptoms. Whether to start treatment immediately after surgery or only after a colonoscopy remains uncertain.

Topics Surgery Monitoring Research

Jargon explained post-operative recurrence colonoscopy prophylaxis

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease

Cochrane Systematic review Aug 2019 Patients and professionals

Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.

Topics Immunosuppressants Surgery Research

Jargon explained postoperative recurrence low certainty evidence post-operative recurrence thiopurine 5-ASA anti-TNF

Enteral nutritional therapy for induction of remission in Crohn's disease

Cochrane Systematic review Apr 2018 Patients and professionals

Compares liquid-only feeding (EN) with steroids for settling a Crohn's flare. Very low-quality evidence suggests steroids may work better in adults, while liquid feeds may work better in children. The type of formula did not seem to matter. The reviewers suggest EN for children, and for adults who can manage it or need to avoid steroids.

Topics Diet and nutrition Steroids Children and young people Research

Jargon explained enteral nutrition polymeric formula elemental diet nasogastric tube elemental feed polymeric feed

Studys 8

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)

New England Journal of Medicine Study Jul 2024 Patients and professionals

A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.

Topics Biologics and newer medicines Research

Jargon explained non-inferiority endoscopic remission anti-TNF

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The Lancet Gastroenterology & Hepatology Study May 2024 Patients and professionals

A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.

Topics Biologics and newer medicines Research About Crohn's disease

Jargon explained top-down treatment step-up treatment biomarker steroid-free remission top-down step-up immunomodulator randomised controlled trial

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE)

The Lancet Study Jun 2022 Patients and professionals

One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.

Topics Biologics and newer medicines Research

Jargon explained head-to-head trial biologic-naive confidence interval

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

The Lancet Study May 2002 Patients and professionals

This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.

Topics Biologics and newer medicines Research

Jargon explained maintenance therapy remission placebo

Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)

New England Journal of Medicine Study May 2023 Patients and professionals

Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.

Topics Medicines Immunosuppressants Research

Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

The Lancet Study Dec 2017 Patients and professionals

CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.

Topics Monitoring Biologics and newer medicines Research

Jargon explained tight control faecal calprotectin CRP mucosal healing treat to target

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease (LIR!C)

The Lancet Gastroenterology & Hepatology Study Nov 2017 Patients and professionals

A Dutch and UK trial in adults whose Crohn's affected a short stretch (under 40 cm) at the end of the small bowel and had not settled with standard medicines. Keyhole surgery to remove that section was compared with infliximab, looking mainly at quality of life at one year. The authors concluded surgery is a reasonable alternative to infliximab for this group. Over about four years, 37% of the infliximab group ended up having surgery anyway.

Topics Surgery Biologics and newer medicines Research

Jargon explained laparoscopic ileocaecal resection terminal ileum quality of life terminal ileitis

Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC)

New England Journal of Medicine Study Apr 2010 Patients and professionals

A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.

Topics Biologics and newer medicines Immunosuppressants Research

Jargon explained combination therapy steroid-free remission mucosal healing randomised controlled trial

Data 2

National IBD Registry

National IBD Registry Data Patients and professionals

The UK registry that collects health data from people with IBD to help improve care and support research. It has been running since 2012 and joined NHS England in 2026. Hospital teams use it to compare their services, and people with IBD can find out what data is collected about them.

Topics Research Monitoring

Jargon explained registry quality improvement

Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018

Alimentary Pharmacology & Therapeutics Data May 2020 Patients and professionals

Using UK GP records from 2000 to 2017, this study found Crohn's became more common, rising from about 220 to 400 per 100,000 people. It predicted about 1 in 90 people in the UK would have IBD by 2025. Colitis was linked to a higher risk of bowel cancer, and both conditions to a somewhat higher risk of death than people without IBD.

Topics About Crohn's disease Cancer risk and screening Research

Jargon explained epidemiology prevalence hazard ratio all-cause mortality

For health professionals

Guidelines 4

British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

British Society of Gastroenterology (Gut) Guideline Jun 2025 For professionals

The 2025 update of the UK specialist guideline for adults with Crohn's or colitis, replacing the 2019 version. It is designed to sit alongside the IBD UK Standards and to encourage GPs to use the national referral pathway for bowel symptoms, so people get diagnosed sooner and more accurately. It was written without drug-company funding and is aimed mainly at the UK, though it can be used elsewhere.

Topics Research Medicines Diagnosis and tests Monitoring

Jargon explained guideline primary care diagnostic pathway

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD)

Gastroenterology Guideline Apr 2021 For professionals

An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.

Topics Monitoring Research Medicines

Jargon explained treat to target endoscopic healing transmural healing biomarker calprotectin CRP clinical remission

ACG Clinical Guideline: Management of Crohn's Disease in Adults

American College of Gastroenterology (Am J Gastroenterol) Guideline Jun 2025 For professionals

The American College of Gastroenterology's 2025 update on diagnosing and treating Crohn's in adults, replacing its 2018 guideline. It reflects how much treatment has changed in recent years. Like other US guidance, it is a useful comparison to UK practice rather than a guide to what the NHS offers.

Topics Medicines Diagnosis and tests Research

Jargon explained idiopathic etiology

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Gut (BMJ) via PubMed Central Guideline Sep 2019 For professionals

The free full text of the 2019 BSG guideline, written with surgeons, specialist nurses, dietitians, radiologists, GPs and Crohn's & Colitis UK. It reviewed a very large body of research to make recommendations for adults with IBD. It has been replaced by the 2025 guideline but is a freely readable reference on diagnosis and assessment.

Topics About Crohn's disease Diagnosis and tests Monitoring Research Medicines Surgery

Jargon explained inflammatory bowel disease consensus guideline IBD

Systematic reviews 7

Efficacy of different psychological interventions for the treatment of inflammatory bowel disease: a systematic review and network meta-analysis

Frontiers in Medicine (PubMed Central) Systematic review 2025 For professionals

A 2025 open-access analysis comparing types of psychological therapy for people with IBD. Mindfulness and CBT reduced depression, acceptance and commitment therapy and CBT reduced anxiety, and CBT ranked well for stress. The authors see these therapies as useful additions to medical care, with uncertain effects on disease activity.

Topics Mental health Research

Jargon explained cognitive behavioural therapy mindfulness acceptance and commitment therapy network meta-analysis

Effectiveness of smoking cessation interventions for smokers with Crohn's disease: a systematic review

Future Science OA (PubMed Central) Systematic review 2023 For professionals

An open-access review of studies on helping people with Crohn's stop smoking. Its background summarises evidence that smokers with Crohn's have more flares and operations and that people who quit can do as well as non-smokers. It concludes that stop-smoking support tailored to people with Crohn's needs more study.

Topics Living well Research

Jargon explained smoking cessation systematic review

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review

Journal of Crohn's and Colitis via PubMed Central Systematic review Feb 2020 For professionals

Reviews the evidence for 'treat to target', where treatment is adjusted not just to symptoms but to measured goals such as a healed bowel lining and normal blood or poo markers. It explains the idea behind the STRIDE targets and notes that firm proof that aiming for healing improves long-term outcomes was still emerging.

Topics Monitoring Research

Jargon explained treat to target mucosal healing biomarker STRIDE

Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy

BMJ Open via PubMed Central Systematic review 2019 For professionals

A UK review pooling studies of how accurate the calprotectin poo test is at detecting IBD in adults with long-standing gut symptoms. Only a handful of the eligible studies were done in general practice, and the results varied too much between studies to compare GP and hospital settings properly. It is useful background on why calprotectin helps but is not a perfect test.

Topics Diagnosis and tests Research

Jargon explained faecal calprotectin sensitivity specificity meta-analysis

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

The Lancet Systematic review Dec 2017 For professionals

A review of population studies from around the world. In Western countries the number of new cases is levelling off but more than 0.3% of people now live with IBD. In newly industrialised countries in Asia, Africa and South America, new cases are rising quickly as lifestyles become more Western.

Topics About Crohn's disease Research

Jargon explained systematic review incidence prevalence population-based study

Non surgical therapy for anal fissure

Cochrane Database of Systematic Reviews Systematic review Feb 2012 For professionals

A Cochrane review of 75 trials of medical treatments for anal fissure, such as GTN ointment, calcium channel blocker creams and botox. Medicines helped some fissures heal but less reliably than surgery, and fissures often came back. Fissures linked to IBD were excluded, so results may not fully apply to Crohn's.

Topics Around the bottom (perianal) Research

Jargon explained anal fissure glyceryl trinitrate sphincterotomy

Studys 13

Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial

The Lancet Gastroenterology & Hepatology Study Nov 2026 For professionals

Five-year follow-up of the PROFILE trial. People who had early top-down treatment were less likely to be admitted to hospital or to develop strictures or fistulas than those treated step-up, with no difference seen in serious infections or cancers, suggesting early treatment may change the course of the disease.

Topics Biologics and newer medicines Research

Jargon explained top-down step-up disease modification stricturing penetrating disease

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY)

The Lancet Study May 2022 For professionals

The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.

Topics Biologics and newer medicines Research

Jargon explained IL-23 maintenance placebo endoscopic response

Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study

BMJ Open via PubMed Central Study Jul 2020 For professionals

A study of more than 11 million people's GP records from 2000 to 2018 tracking new IBD diagnoses in the UK. It found new cases in adults were stable or falling, but UK rates are among the highest reported anywhere, with a large rise in new diagnoses among teenagers.

Topics About Crohn's disease Research

Jargon explained incidence prevalence cohort study primary care

The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017

The Lancet Gastroenterology & Hepatology via PubMed Central Study Oct 2019 For professionals

Part of the Global Burden of Disease project, estimating about 6.8 million people with IBD worldwide in 2017. Rates were highest in wealthier countries, and the UK had the second highest age-adjusted rate after the USA.

Topics About Crohn's disease Research

Jargon explained prevalence inflammatory bowel disease disability-adjusted life years age-standardised rate

The treatment-naive microbiome in new-onset Crohn's disease

Cell Host & Microbe Study Mar 2014 For professionals

A large study of the gut bacteria of children newly diagnosed with Crohn's, before any treatment. It found a clear pattern: more of certain potentially harmful bacteria and fewer of some helpful groups. Antibiotics made the imbalance worse. Samples from the rectum lining looked promising as a possible early diagnostic test.

Topics About Crohn's disease Research Children and young people

Jargon explained microbiome dysbiosis treatment-naive

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

Nature Study Nov 2012 For professionals

A huge international genetics study that mapped many gene regions linked to Crohn's and colitis. Many of these are shared with other immune conditions such as ankylosing spondylitis and psoriasis, and with the body's response to bacteria such as those that cause TB. It shows IBD risk is spread across many genes, each adding a small amount.

Topics About Crohn's disease Research

Jargon explained genome-wide association study locus immune-mediated disease

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

Nature Study May 2001 For professionals

One of two papers published together in 2001 that found the first gene firmly linked to Crohn's, NOD2. A change in this gene produces a faulty version of a protein that normally helps the immune system recognise bacteria. It pointed to an abnormal reaction to gut bacteria as part of what causes Crohn's.

Topics About Crohn's disease Research

Jargon explained NOD2 mutation susceptibility gene innate immunity

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

Nature Study May 2001 For professionals

The companion to the other 2001 NOD2 paper. It found several variants of the NOD2 gene linked to Crohn's, all in the part of the protein that senses bits of bacteria. It suggested that people with these variants may handle gut bacteria differently, a key step in understanding the causes of Crohn's.

Topics About Crohn's disease Research

Jargon explained NOD2 gene variant genetic susceptibility

Evaluation of Long-Term Outcomes of Crohn's Disease Complicated by Intra-Abdominal Abscess: A Retrospective International Cohort Study

Journal of Clinical Medicine Study Apr 2026 For professionals

A look back at 157 adults with Crohn's and a single abscess inside the tummy, treated at 14 specialist centres in nine countries. People whose abscess was first drained through the skin with a scan-guided tube had fewer hospital admissions and fewer complications afterwards than those who went straight to planned surgery, though most still had an operation later. The authors say drainage first can be the preferred start, but the study was not randomised.

Topics Complications Surgery Research

Jargon explained intra-abdominal abscess percutaneous drainage resection penetrating Crohn's

Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial

The Lancet Gastroenterology & Hepatology via PubMed Central Study Jun 2018 For professionals

A UK trial at eight NHS hospitals comparing MRI enterography with bowel ultrasound in 284 people with new or relapsing Crohn's. Both were very good at spotting small bowel Crohn's and were judged valid first tests and alternatives to colonoscopy of the ileum, but MRI was more accurate at mapping how much bowel was affected. The authors concluded MRI is generally preferred in the NHS where available.

Topics Diagnosis and tests Monitoring Research

Jargon explained MRI enterography intestinal ultrasound small bowel sensitivity

Oral Cyanocobalamin is Effective in the Treatment of Vitamin B12 Deficiency in Crohn's Disease

Nutrients Study Mar 2017 For professionals

A Spanish multi-centre study of 94 people with Crohn's and low B12, many after ileal surgery. Most who took B12 by mouth reached normal levels, suggesting tablets may be an option for some instead of injections. Treatment choices should be made with your own team.

Topics Anaemia Diet and nutrition Research

Jargon explained vitamin b12 deficiency cyanocobalamin ileal resection

Crohn's disease management after intestinal resection: a randomised trial (POCER)

The Lancet Study Feb 2015 For professionals

A trial of how to stop Crohn's returning after bowel surgery. Treating people according to their risk, checking with a colonoscopy at six months and stepping up treatment if the disease had come back worked better than standard drug treatment alone. It also showed that even low-risk patients need monitoring.

Topics Surgery Monitoring Research

Jargon explained post-operative recurrence colonoscopy step-up resection

Guides 2

Crohn's disease: What are the causes and risk factors?

NICE CKS Guide May 2024 For professionals

Explains that no single cause of Crohn's has been proven and that it is thought to be an immune-driven condition set off by environmental triggers in people whose genes make them susceptible. It covers family history, smoking (which raises the risk of Crohn's, unlike UC, and is linked to flare-ups and surgery), a past bout of infectious gastroenteritis and other factors that have been studied.

Topics About Crohn's disease Research

Jargon explained immune-mediated gastroenteritis appendicectomy

Crohn's disease: How common is it?

NICE Clinical Knowledge Summaries Guide May 2024 For professionals

NICE's GP summary on how common Crohn's is. It says exact figures are not known because studies count cases differently, that new cases are thought to be stable or falling in Europe and the US but rising in newly industrialised countries, and that Crohn's usually starts in the teenage and young adult years, with a median age at diagnosis of about 30. Men and women are affected about equally.

Topics About Crohn's disease Research

Jargon explained incidence prevalence

Data 1

The incidence and prevalence of inflammatory bowel disease in UK primary care: a retrospective cohort study of the IQVIA Medical Research Database

BMC Gastroenterology Data Mar 2021 For professionals

Another big UK GP-records study, covering 2006 to 2016. It found IBD rose by about a third over that time to roughly 1.4% of patients, higher than earlier estimates. The authors point out that the answer depends heavily on how a 'case' is defined, which may explain why older figures were lower.

Topics About Crohn's disease Research

Jargon explained retrospective cohort study prevalence incidence

Tools 1